Deck 11: Measuring Health-Related Quality of Life and Other Outcomes

Question 1

Blumenthal contended that the most important new development in our current understanding of medical outcomes was the recognition that it is patients who

A) Decide which procedure is appropriate
B) Define which outcomes are important and whether they were achieved
C) Inform physicians of the consequences of their actions
D) Determine insurance plan benefits

Answer 1

Define which outcomes are important and whether they were achieved

Question 2

Medical outcomes are most important ultimately for

A) Patients
B) Physicians
C) Health insurance plans
D) Medical Journals

Answer 2

Patients

Question 3

Duration of life is

A) The most important measure of life
B) A structure of care measure of life
C) Not the same as measuring quality of life
D) Addresses essential components of functioning

Answer 3

Not the same as measuring quality of life

Question 4

Evaluation of HRQL instruments must include

A) Reliability
B) Scales
C) Validity
D) a & c

Question 5

QALY is a

A) Traditional measure of life expectancy
B) Traditional measure of infant mortality
C) Years of wellness scored on a continuum
D) Measure of disability Days

Question 6

The IOM has suggested the QALY be

A) Used in evaluation of public health programs
B) Not be considered as a population health measure
C) Be tied to infant mortality rates
D) None of the above

Question 7

Cost effectiveness decisions can best be made

A) When program are eliminated
B) When interventions that produce the greatest amount of health using existing resources are identified
C) When high cost administrators are not involved in programs
D) All of the above

Question 8

Feedback to patients regarding medical outcomes is important as

A) Patients have to make choices about their care based on info available
B) Patients have to advise their physicians on their insurance plan
C) Physicians have to tell the patient what therapies the physician likes best
D) Hospitals make the decisions for the patients without their input

Question 9

SF-36 is

A) A new drug
B) An MOS short form 36
C) Diabetes trial observation instrument
D) Cost per QALY

Question 10

Comparative Effectiveness Research

A) Concentrates on the evaluation of the benefits and risks of healthcare from the patient perspective
B) Concentrates on the evaluation of benefits and risks of healthcare from the physician perspective
C) Concentrates on the evaluation of benefits and risks of healthcare from the hospital's perspective
D) Concentrates on the evaluation of the benefits and risks of healthcare from the health insurance plan

Question 11

The number of quality of life publications has grown rapidly since 1972.

Question 12

Medical Outcomes management is not used by insurance plans.

Question 13

Inclusion of QALY is supported as a key component of outcomes management.

Question 14

Process of care refers to how medical and other services are organized in a particular organization.

Question 15

Outcomes of care may include HRQL.

Question 16

Reliability and validity must be established on HRQL scales and instruments.

Question 17

IOM does not recommend QALY measures for population health evaluation.

Question 18

Several authors have used HRQL measures to estimate the effectiveness of clinical interventions.

Question 19

Comparative effectiveness research has a patient perspective focus.

Question 20

The ACA has not required a patient centered outcome focus.